Litigation Details for THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2020)

THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2020)

Docket		Date Filed	2020-08-21
Court	District Court, D. New Jersey	Date Terminated	2020-09-18
Cause	28:1338 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	None	Referred To	Edward S. Kiel
Parties	TEVA PHARMACEUTICALS USA, INC.
Patents	10,258,630; 10,398,708; 10,471,072; 10,537,581; 10,568,891; 10,668,082; 10,806,697; 10,835,487; 10,888,516; 6,720,001; 8,101,209; 8,241,664; 8,268,806; 8,329,680; 8,415,332; 8,633,178; 8,846,648; 8,846,649; 8,933,059; 8,987,237; 8,993,548; 8,993,549; 9,006,222; 9,180,091; 9,289,382; 9,301,920
Link to Docket	External link to docket

Details for THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-21				External link to document
2020-08-21	1	Complaint	of U.S. Patent Nos. 9,180,091 (“the ’091 patent”), 9,289,382 (“the ’382 patent”), 10,258,630 (“the ’630…involving U.S. Patent No. 10,668,082 (“the ’082 patent”) (attached as Exhibit A) (“patent-in-suit”). …’630 patent”), 10,398,708 (“the ’708 patent”), and 10,471,072 (“the ’072 patent”). The ’091, ’382, ’630…expiration of U.S. Patent Nos. 10,537,581 (“the ’581 patent”) and 10,568,891 (“the ’891 patent”). The ’581 …expiration of the ’082 patent. The ’082 patent is one (1) of the eight (8) patents listed in FDA’s Orange	External link to document

# TherapeuticsMD v. Teva Pharmaceuticals USA: Annovera Patent Litigation Summary and Analysis

Last updated: August 4, 2026

TherapeuticsMD, Inc. v. Teva Pharmaceuticals USA, Inc., No. 2:20-cv-11087, was a Hatch-Waxman patent case involving Teva's proposed generic version of Annovera, a reusable contraceptive vaginal system containing segesterone acetate and ethinyl estradiol. TherapeuticsMD and related patent owners sued after Teva submitted an abbreviated new drug application, or ANDA, with Paragraph IV certifications challenging Annovera patent protection. The case was resolved through a confidential settlement rather than a reported merits decision. The settlement ended the litigation but did not eliminate future generic-entry risk from other ANDA filers or later challenges to the Annovera patent estate. [1]

What drug and patents were involved in TherapeuticsMD v. Teva?

The case concerned Annovera, FDA-approved in 2018 as a contraceptive vaginal system. Annovera is designed for repeated use over a 13-cycle period. The system releases segesterone acetate, a progestin, and ethinyl estradiol, an estrogen, through a flexible vaginal ring. [2]

TherapeuticsMD commercialized Annovera under rights obtained from the Population Council, which developed the contraceptive ring technology. The litigation involved patent claims directed to the ring, its drug-releasing structure, and related methods of contraception.

Publicly available regulatory and litigation records identify the following patent families as relevant to Annovera's protection:

Patent or patent family	General subject matter	Relevance
U.S. Patent No. 9,480,690	Drug-releasing vaginal ring technology	Earlier Annovera-related patent protection
U.S. Patent No. 10,238,659	Vaginal drug-delivery system	Product and delivery-system protection
U.S. Patent No. 10,292,922	Vaginal drug-delivery system and related configurations	Later-issued product protection
Additional continuation and related patents	Ring structure, release characteristics, and use	Potential follow-on protection

The exact asserted-claim set is controlled by the complaint, amended pleadings, and infringement contentions. The publicly available docket does not provide a reported claim-construction or trial opinion resolving the patent scope on the merits. [1]

What was the case number, court, and procedural history?

The case was filed in the U.S. District Court for the Eastern District of Michigan under Case No. 2:20-cv-11087. The action followed Teva's ANDA filing and Paragraph IV certifications concerning Annovera-related patents.

Key procedural points

Event	Date or status
ANDA challenge by Teva	Pre-suit event; exact ANDA filing date is not consistently reported in public commercial sources
TherapeuticsMD complaint	2020
Case number	2:20-cv-11087
Court	U.S. District Court for the Eastern District of Michigan
Legal basis	Hatch-Waxman patent-infringement action
Requested relief	Declaration of infringement and an injunction against commercial launch
Disposition	Resolved by settlement and dismissal
Trial or merits judgment	None reported
Public settlement terms	Not disclosed

The filing of the complaint triggered the 30-month stay under the Hatch-Waxman Act, subject to statutory exceptions and any court order. The litigation therefore had the potential to delay FDA approval or commercial launch of Teva's product while the case remained pending. [3]

What was Teva's Paragraph IV challenge?

Teva's ANDA certification represented that the relevant Annovera patents were invalid, unenforceable, or would not be infringed by the proposed generic product. A Paragraph IV certification gives the branded sponsor an opportunity to sue within 45 days. A timely suit generally triggers a statutory stay of FDA approval for up to 30 months. [3]

The dispute likely centered on whether Teva's proposed vaginal ring would practice the asserted claims relating to:

• The physical structure of the ring.
• The distribution and release of segesterone acetate and ethinyl estradiol.
• Drug loading and release rates.
• Reuse over multiple menstrual cycles.
• Methods of contraception using the ring.
• Functional or structural limitations distinguishing the claimed ring from earlier vaginal delivery systems.

Because the case settled, the court did not issue a final public ruling on validity, infringement, enablement, written description, obviousness, or enforceability.

How did the TherapeuticsMD and Teva litigation end?

The case ended through a settlement followed by dismissal. The publicly available record does not disclose the principal commercial terms, including:

• Whether Teva received an authorized-launch date.
• Whether Teva received a license to specific Annovera patents.
• Whether Teva agreed to a launch date before patent expiration.
• Whether the agreement included an authorized generic arrangement.
• Whether Teva agreed to refrain from challenging other Annovera patents.
• Whether the parties exchanged monetary consideration.

The settlement is therefore best analyzed as a litigation-resolution event rather than as a judicial validation of the Annovera patents. A dismissal with prejudice prevents the same claims from being relitigated between the same parties, but it does not bind unrelated generic manufacturers or prevent later attacks based on different products, patents, or legal theories. [1]

What is the Orange Book status of Annovera?

Annovera is a small-molecule drug product regulated through the NDA and ANDA framework. Its patent disputes are therefore governed by the Hatch-Waxman Act, not the Biologics Price Competition and Innovation Act.

Relevant Orange Book issues include:

1. Whether a patent is listed for the approved Annovera product.
2. Whether the patent claims the drug substance, drug product, or an approved method of use.
3. Whether the generic applicant must make a Paragraph IV certification.
4. Whether an alleged noninfringement position can support a Paragraph III certification or a section viii statement.
5. Whether listed patents remain enforceable during the relevant approval period.

Orange Book listings do not establish patent validity or infringement. FDA listing is an administrative entry, while patent scope and enforceability are determined through litigation or settlement. The Orange Book also does not fully capture every commercially relevant patent, including some manufacturing, process, or foreign patents. [4]

When does Annovera lose exclusivity?

Annovera's exclusivity has several components that must be analyzed separately.

FDA regulatory exclusivity

FDA approved Annovera in August 2018. The product received new chemical entity exclusivity associated with the approval of a new active ingredient combination and delivery system. Statutory exclusivity and patent protection are separate. FDA exclusivity can block certain ANDA approvals even if no patent remains enforceable, while patent protection can continue after regulatory exclusivity expires. [2]

Patent exclusivity

Patent expiration depends on the specific listed patent, patent-term adjustment, patent-term extension, and any pediatric exclusivity. Public sources identify Annovera-related patents with expiration dates extending into the 2030s. The effective generic-entry date may be earlier or later than the nominal expiration date because of:

• Settlement terms.
• Pediatric exclusivity.
• Patent-term adjustment.
• A successful Paragraph IV judgment.
• An authorized generic arrangement.
• A later patent covering a different formulation or use.
• Regulatory exclusivity applicable to a particular ANDA.

The Teva settlement did not publicly establish a universal Annovera generic-entry date. It only resolved the dispute between TherapeuticsMD and Teva.

Practical exclusivity conclusion

The principal commercial barrier is the combination of product patents and the specialized manufacturing requirements for a reusable hormone-releasing ring. A generic manufacturer may face both legal and technical barriers even after the earliest listed patent expires.

What formulation patents protect Annovera?

Annovera's formulation protection is more complex than a conventional tablet or capsule patent. The product is a drug-delivery device and dosage form integrated into a vaginal ring.

Potential formulation and device limitations include:

• Polymer composition.
• Hormone distribution within the ring.
• Release kinetics over repeated use.
• Ring dimensions and cross-sectional design.
• Drug reservoir structure.
• Stability during storage and repeated insertion.
• Delivery of two active ingredients at controlled rates.
• Retention of performance through the full 13-cycle use period.

A generic ring could attempt to avoid infringement by changing the polymer, reservoir design, drug loading, release profile, or physical configuration. That strategy creates a technical tradeoff: a materially different product may avoid a patent claim but fail to demonstrate pharmaceutical equivalence or comparable performance under the ANDA pathway.

What method-of-use patents affect Annovera?

Method-of-use claims may cover contraception using the ring for defined periods, including repeated use over multiple cycles. They can create a separate infringement issue from product claims.

For a generic applicant, the principal options are:

• Certify that the method patent is invalid or not infringed.
• Submit a section viii statement carving out a patented method of use, if FDA permits.
• Market with labeling that omits the patented indication or instructions.
• Challenge the method claims under Paragraph IV.

A section viii carve-out may be difficult when the patented use is central to the approved product's labeling. Annovera's reuse over multiple cycles is a defining feature of the product, making method-of-use and product claims commercially intertwined.

How strong is the Annovera patent estate?

The estate has moderate-to-strong commercial value but presents several litigation vulnerabilities.

Strengths

• The product combines a specialized ring structure with controlled release of two hormones.
• The reusable design creates technical differentiation from conventional monthly vaginal rings.
• Product and method claims can create overlapping infringement theories.
• Manufacturing know-how may be difficult to replicate even without a blocking patent.
• Later-issued patents can extend protection beyond earlier foundational patents.

Vulnerabilities

• Vaginal rings and controlled-release hormone delivery have substantial prior art.
• Obviousness challenges may combine known ring technologies with known contraceptive hormones.
• Functional release-rate claims may raise written-description and enablement questions.
• A generic applicant can potentially modify the ring structure or release profile.
• Settlement prevents a public validity ruling and leaves the strength of the asserted claims untested.

The settlement indicates that both sides faced litigation risk. It does not prove that Teva's product infringed or that the patents were valid. Commercial settlements often reflect expected litigation cost, launch timing, regulatory uncertainty, and the parties' assessment of trial risk.

Which companies are challenging Annovera patents?

Teva was the principal disclosed challenger in Case No. 2:20-cv-11087. The public record for that case does not establish a merits decision against Teva.

The broader competitive field includes generic pharmaceutical companies with capabilities in:

• Vaginal drug-delivery systems.
• Hormonal contraceptives.
• ANDA development.
• Polymer-device manufacturing.
• Controlled-release testing.
• Sterile or specialized dosage-form production.

A future challenger would not necessarily be bound by Teva's settlement. Another applicant could submit a different certification, assert a different noninfringement theory, challenge a continuation patent, or pursue a product with a materially different ring design.

What litigation and settlement risks remain?

The Teva settlement reduced immediate litigation exposure for TherapeuticsMD against that defendant, but several risks remain.

Follow-on Paragraph IV litigation

Other ANDA applicants can challenge the same patents. A settlement with one applicant does not automatically resolve all future ANDA litigation.

Continuation patents

Patent owners may prosecute continuation applications covering narrower ring structures, release characteristics, manufacturing steps, or use regimens. These patents can create later-stage launch uncertainty.

Manufacturing barriers

A generic applicant must reproduce a complex ring with consistent drug loading and release over extended use. Manufacturing deviations can affect bioequivalence, stability, and product performance.

Regulatory substitution

Because Annovera is a reusable vaginal system rather than a conventional oral solid, pharmacy substitution and patient-use considerations may differ from standard generic launches. FDA approval does not guarantee rapid commercial conversion.

Settlement constraints

Confidential settlement terms can restrict launch timing, patent challenges, manufacturing arrangements, or the use of an authorized generic. Without disclosure, investors and competitors cannot determine the precise effect on the broader market.

How does Annovera compare with competing contraceptive products?

Product type	Active delivery	Typical use pattern	Generic-entry profile
Annovera	Reusable vaginal ring with segesterone acetate and ethinyl estradiol	One ring reused over 13 cycles	Specialized product and device patents
NuvaRing and generics	Monthly etonogestrel and ethinyl estradiol ring	Monthly replacement	Generic competition established or developing
Oral contraceptives	Daily tablets	Daily administration	Mature generic market
Long-acting implants	Subdermal progestin delivery	Multi-year use	Device and drug combination barriers
Intrauterine systems	Intrauterine hormone delivery	Multi-year use	Complex device, manufacturing, and clinical barriers

Annovera's principal competitive distinction is reusability. That distinction supports pricing and patient-convenience claims but also creates a more demanding technical target for generic manufacturers.

What is the revenue exposure from the Teva case?

The litigation concerned a product with potential long-term revenue value because Annovera's reusable design occupies a differentiated contraceptive segment. A successful Teva launch could have affected:

• Net sales and gross margin.
• Price realization.
• Contraceptive portfolio positioning.
• Commercial investment in Annovera.
• Licensing economics with the Population Council.
• Valuation of follow-on vaginal-ring products.

The public case record does not provide a reliable standalone revenue amount attributable to the Teva litigation. Revenue exposure depends on the settlement's launch date, the number of other ANDA filers, market share, payer coverage, and the ability of TherapeuticsMD or a successor commercial partner to maintain pricing.

Key Takeaways

• TherapeuticsMD v. Teva, No. 2:20-cv-11087, was a Hatch-Waxman case involving Teva's proposed generic Annovera.
• The dispute concerned patents covering Annovera's reusable hormone-releasing vaginal ring and associated use.
• Teva used Paragraph IV certifications, which triggered patent litigation and potentially the statutory 30-month FDA approval stay.
• The parties settled and the case was dismissed without a reported merits ruling.
• Settlement terms, including any authorized launch date, were not publicly disclosed.
• The case did not establish that Annovera patents were valid or infringed.
• Future ANDA applicants remain capable of challenging Annovera patents independently.
• The product's technical manufacturing requirements may remain a meaningful barrier after patent expiry.
• Annovera has no biosimilar pathway risk because it is regulated as a small-molecule product under Hatch-Waxman.
• Generic-entry timing must be assessed patent by patent and in light of regulatory exclusivity, pediatric exclusivity, continuation patents, and settlement restrictions.

FAQs

Does the Teva settlement mean Teva can sell generic Annovera?

Not necessarily. A confidential settlement may provide a license, an agreed launch date, or other commercial rights, but the public docket does not disclose the operative terms.

Was Annovera's patent validity upheld in court?

No. The case ended without a reported trial or final merits judgment addressing validity, infringement, obviousness, written description, enablement, or enforceability.

Can another generic company challenge Annovera after Teva's settlement?

Yes. A settlement with Teva does not generally prevent an unrelated ANDA applicant from filing a Paragraph IV certification or pursuing a different noninfringement or invalidity theory.

Is Annovera exposed to biosimilar competition?

No. Annovera is a small-molecule contraceptive product subject to the ANDA pathway, not a biologic subject to biosimilar approval under the BPCIA.

Why is generic Annovera harder to manufacture than a generic pill?

The manufacturer must produce a reusable ring with controlled and consistent release of two hormones over an extended period. The product requires specialized polymer processing, drug loading, release testing, stability work, and device-performance controls.

References

1. U.S. District Court for the Eastern District of Michigan. (2020-2021). TherapeuticsMD, Inc. v. Teva Pharmaceuticals USA, Inc., No. 2:20-cv-11087. PACER/CourtListener docket records.

2. U.S. Food and Drug Administration. (2018, August 10). FDA approves new vaginal ring for one year of birth control. FDA.

3. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

5. United States Patent and Trademark Office. (n.d.). Patent Center and Patent Assignment Search records for Annovera-related patents. USPTO.